Agilent (A) 10-Q 2 Mar 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jan. 31, 2023	Feb. 24, 2023
Document and Entity Information [Abstract]
Entity Registrant Name	AGILENT TECHNOLOGIES, INC.
Document Type	10-Q
Document Fiscal Period Focus	Q1
Document Period End Date	Jan. 31, 2023
Current Fiscal Year End Date	--10-31
Document Fiscal Year Focus	2023
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Entity Central Index Key	0001090872
Entity File Number	001-15405
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0518772
Entity Address, Address Line One	5301 Stevens Creek Blvd.,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95051
City Area Code	(800)
Local Phone Number	227-9770
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	A
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		295,701,853

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Net revenue:
Net revenue	$ 1,756	$ 1,674
Costs and expenses:
Cost of revenue	788	764
Research and development	123	117
Selling, general and administrative	419	417
Total costs and expenses	1,330	1,298
Income from operations	426	376
Interest income	9	1
Interest expense	(25)	(21)
Other income (expense), net	0	(37)
Income before taxes	410	319
Provision for income taxes	58	36
Net income	$ 352	$ 283
Net income per share
Basic	$ 1.19	$ 0.94
Diluted	$ 1.19	$ 0.93
Weighted average shares used in computing net income per share:
Basic	296	301
Diluted	297	303
Product
Net revenue:
Net revenue	$ 1,323	$ 1,263
Costs and expenses:
Cost of revenue	556	545
Service and Other
Net revenue:
Net revenue	433	411
Costs and expenses:
Cost of revenue	$ 232	$ 219

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Net income	$ 352	$ 283
Other comprehensive income (loss):
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $(9) and $2	(22)	6
Amount reclassified into earnings related to derivative instruments, net of tax benefit of $(2) and $(1)	(4)	(2)
Foreign currency translation, net of tax expense (benefit) of $(1) and $0	91	(27)
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax expense of $0 and $2	2	7
Other comprehensive income (loss)	67	(16)
Total comprehensive income	$ 419	$ 267

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Other comprehensive income (loss), tax, parenthetical disclosures
Unrealized gain (loss) on derivative instruments, tax	$ (9)	$ 2
Amounts reclassified into earnings related to derivative instruments, tax	(2)	(1)
Foreign currency translation, tax	(1)	0
Net defined benefit pension cost and post retirement plan costs, tax
Change in actuarial net loss, tax	$ 0	$ 2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($) $ in Millions	Jan. 31, 2023	Oct. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,250	$ 1,053
Accounts receivable, net	1,459	1,405
Inventory	1,111	1,038
Other current assets	258	282
Total current assets	4,078	3,778
Property, plant and equipment, net	1,147	1,100
Goodwill	3,983	3,952
Other intangible assets, net	810	821
Long-term investments	188	195
Other assets	713	686
Total assets	10,919	10,532
Current liabilities:
Accounts payable	540	580
Employee compensation and benefits	296	455
Deferred revenue	521	461
Short-term debt	238	36
Other accrued liabilities	341	329
Total current liabilities	1,936	1,861
Long-term debt	2,733	2,733
Retirement and post-retirement benefits	99	97
Other long-term liabilities	542	536
Total liabilities	5,310	5,227
Commitments and Contingencies (Note 9 and 12)
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 296 million shares at January 31, 2023 and 295 million shares at October 31, 2022, issued and outstanding	3	3
Additional paid-in-capital	5,345	5,325
Retained earnings	541	324
Accumulated other comprehensive loss	(280)	(347)
Total stockholder's equity	5,609	5,305
Total liabilities and equity	$ 10,919	$ 10,532

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) - $ / shares shares in Thousands	Jan. 31, 2023	Oct. 31, 2022
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	125,000	125,000
Preferred Stock, Shares Issued	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	2,000,000	2,000,000
Common Stock, Shares, Issued	296,000	295,000
Common Stock, Shares, Outstanding	296,000	295,000

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Cash flows from operating activities
Net income	$ 352	$ 283
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	67	82
Share-based compensation	44	44
Deferred taxes	4	24
Excess and obsolete inventory related charges	7	5
Net (gain) loss on equity securities	10	47
Change in fair value of contingent consideration	1	3
Other non-cash expense, net	1	0
Changes in assets and liabilities:
Accounts receivable,net	(5)	(46)
Inventory	(69)	(54)
Accounts payable	(27)	37
Employee compensation and benefits	(174)	(210)
Other assets and liabilities	85	40
Net cash provided by operating activities	296	255
Cash flows from Investing activities:
Investments in property, plant and equipment	(76)	(75)
Payments to acquire equity securities	(1)	(3)
Proceeds from Sale of Loans Receivable	3	1
Payment in exchange for convertible note	2	0
Proceeds from sale of equity securities	4	0
Acquisitions of businesses and intangible assets, net of cash acquired	(30)	0
Net cash used in investing activities	(104)	(79)
Cash flows from financing activities:
Issuance of common stock under employee stock plans	35	27
Payment of taxes related to net share settlement of equity awards	(51)	(63)
Payment of dividends	(67)	(63)
Payment for Contingent Consideration	(62)	0
Proceeds from Commercial Paper	527	240
Repayments of commercial paper	(324)	(240)
Treasury stock repurchases	(75)	(447)
Net cash used in financing activities	(17)	(546)
Effect of Exchange Rate Movements	22	(4)
Net increase (decrease) in cash, cash equivalents and restricted cash	197	(374)
Cash, cash equivalents and restricted cash at beginning of period	1,056	1,490
Cash, cash equivalents and restricted cash at end of period	1,253	1,116
Supplemental cash flow information:
Income tax paid, net	17	22
Interest payments	15	18
Property, Plant and Equipment
Supplemental cash flow information:
Net change in property, plant and equipment included in Accounts Payable and Accrued Liabilities increase (decrease)	$ (20)	$ (7)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENT OF EQUITY - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total Stockholder's Equity
Beginning Balance (in Shares) at Oct. 31, 2021		302,208
Beginning Balance at Oct. 31, 2021		$ 3	$ 5,320	$ 348	$ (282)	$ 5,389
Components of comprehensive income, net of tax
Net income	$ 283			283		283
Other comprehensive income (loss)	(16)				(16)	(16)
Total comprehensive income, net of tax						267
Cash dividends declared				63		63
Share-based awards issued, net of tax (in shares)		972
Share-based awards issued			(36)			(36)
Stock Repurchased and Retired During Period, Shares		(2,907)
Stock Repurchased and Retired During Period, Value			(38)	(409)		(447)
Share-based compensation			44			44
Ending Balance (in Shares) at Jan. 31, 2022		300,273
Ending Balance at Jan. 31, 2022		$ 3	5,290	159	(298)	5,154
Beginning Balance (in Shares) at Oct. 31, 2022		295,259
Beginning Balance at Oct. 31, 2022		$ 3	5,325	324	(347)	5,305
Components of comprehensive income, net of tax
Net income	352			352		352
Other comprehensive income (loss)	$ 67				67	67
Total comprehensive income, net of tax						419
Cash dividends declared				67		67
Share-based awards issued, net of tax (in shares)		1,061
Share-based awards issued			(17)			(17)
Stock Repurchased and Retired During Period, Shares		(499)
Stock Repurchased and Retired During Period, Value			(7)	(68)		(75)
Share-based compensation			44			44
Ending Balance (in Shares) at Jan. 31, 2023		295,821
Ending Balance at Jan. 31, 2023		$ 3	$ 5,345	$ 541	$ (280)	$ 5,609

CONDENSED CONSOLIDATE STATEMENT

CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Statement of Stockholders' Equity [Abstract]
Dividends Declared per share	$ 0.225	$ 0.210
Share-based Award, Tax	$ 51	$ 63

OVERVIEW, BASIS OF PRESENTATION

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes)	3 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview. Agilent Technologies, Inc. ("we," "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three months ended January 31, 2023 and 2022 pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2022 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2022. In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of January 31, 2023 and October 31, 2022, condensed consolidated statement of comprehensive income (loss) for the three months ended January 31, 2023 and 2022, condensed consolidated statement of operations for the three months ended January 31, 2023 and 2022, condensed consolidated statement of cash flows for the three months ended January 31, 2023 and 2022 and condensed consolidated statement of equity for the three months ended January 31, 2023 and 2022. Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement benefit plan assumptions and accounting for income taxes. Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows: January 31, October 31, 2023 2022 (in millions) Cash and cash equivalents $ 1,250 $ 1,053 Restricted cash included in other assets 3 3 Total cash, cash equivalents and restricted cash $ 1,253 $ 1,056 Leases. As of January 31, 2023 and October 31, 2022, operating lease right-of-use assets where we are the lessee were $ 155 million 150 million 159 million 152 million Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of January 31, 2023 and October 31, 2022, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value ("RDFV"), depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of January 31, 2023 and October 31, 2022, the total carrying value of investments and loans in privately held companies considered as VIEs was $71 million and $87 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the condensed consolidated balance sheet. Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. As of January 31, 2023 and October 31, 2022, the fair value of the term loans approximates its carrying value. As of January 31, 2023, the fair value of our senior notes was $1,859 million with a carrying value of $2,133 million. This compares to the fair value of our senior notes of $1,754 million with a carrying value of $2,133 million as of October 31, 2022. The change in the fair value compared to carrying value in the three months ended January 31, 2023 is primarily due to decreased market interest rates. The fair value was calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments and contingent consideration.

NEW ACCOUNTING PRONOUNCEMENTS (

NEW ACCOUNTING PRONOUNCEMENTS (Notes)	3 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	NEW ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Pronouncements In November 2021, the FASB issued updates to increase the transparency in the annual disclosure requirements relating to government assistance received by business entities in Topic 832, Government Assistance. The guidance requires certain disclosures about transactions with a government that are accounted for by applying a grant or contribution model. On November 1, 2022, we adopted this guidance which did not have a material impact on our condensed consolidated financial statements and disclosures. Accounting Pronouncements Not Yet Adopted There were no additions to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2022. Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our condensed consolidated financial statements upon adoption.

REVENUE (Notes)

REVENUE (Notes)	3 Months Ended
	Jan. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer	REVENUE The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Three Months Ended January 31, 2023 2022 Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total (in millions) Revenue by Region Americas $ 332 $ 154 $ 201 $ 687 $ 317 $ 132 $ 188 $ 637 Europe 259 98 99 456 252 98 101 451 Asia Pacific 442 129 42 613 407 129 50 586 Total $ 1,033 $ 381 $ 342 $ 1,756 $ 976 $ 359 $ 339 $ 1,674 The following table presents the company’s total revenue disaggregated by end markets and by revenue type: Three Months Ended January 31, 2023 2022 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 639 $ 602 Chemicals and Advanced Materials 406 373 Diagnostics and Clinical 239 243 Food 160 158 Academia and Government 146 141 Environmental and Forensics 166 157 Total $ 1,756 $ 1,674 Revenue by Type Instrumentation $ 759 $ 691 Non-instrumentation and other 997 983 Total $ 1,756 $ 1,674 Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services. Contract Balances Contract Assets Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheet. The balances of contract assets as of January 31, 2023 and October 31, 2022 were $276 million and $275 million, respectively. Contract Liabilities The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2023: Contract (in millions) Ending balance as of October 31, 2022 $ 557 Net revenue deferred in the period 246 Revenue recognized that was included in the contract liability balance at the beginning of the period (196) Change in deferrals from customer cash advances, net of revenue recognized (5) Currency translation and other adjustments 21 Ending balance as of January 31, 2023 $ 623 During the three months ended January 31, 2022 revenue recognized that was included in the contract liability balance at October 31, 2021 was $191 million. Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the condensed consolidated balance sheet based on the timing of when we expect to complete our performance obligation. Contract Costs Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the three months ended January 31, 2023 and was included in other current and long-term assets on the condensed consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities. Transaction Price Allocated to the Remaining Performance Obligations We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.

SHARE-BASED COMPENSATION (Notes

SHARE-BASED COMPENSATION (Notes)	3 Months Ended
	Jan. 31, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION We account for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock options, restricted stock units, employee stock purchases made under our employee stock purchase plan and performance share awards granted to selected members of our senior management under the long-term performance plan (“LTPP”) based on estimated fair values. We have two LTPP performance stock award programs, which are administered under the 2018 Stock Plan, for our executive officers and other key employees. Participants in our LTPP Total Stockholders’ Return (“TSR”) and LTPP Earnings Per Share (“EPS”) programs are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets for the programs are met. The LTPP-TSR awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the TSR set at the beginning of the performance period. The LTPP-EPS awards are based on the company’s EPS performance over a three-year period. The performance targets for the LTPP-EPS for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards are subject to a one-year post-vest holding period. The final LTPP award may vary from 0 percent to 200 percent of the target award. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. In fiscal year 2021, we resumed granting stock options. Stock options granted under the 2018 Stock Plan may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options generally vest at a rate of 25 percent per year over a period of four years from the date of grant with a maximum contractual term of ten years. The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. We issue new shares of common stock when employee stock options are exercised. The impact on our results for share-based compensation was as follows: Three Months Ended January 31, 2023 2022 (in millions) Cost of products and services $ 13 $ 11 Research and development 5 6 Selling, general and administrative 26 28 Total share-based compensation expense $ 44 $ 45 At January 31, 2023 and October 31, 2022, no share-based compensation was capitalized within inventory. The following assumptions were used to estimate the fair value of awards granted. Three Months Ended January 31, 2023 2022 Stock Option Plans: Weighted average risk-free interest rate 3.9% 1.3 % Dividend yield 0.6% 0.5 % Weighted average volatility 28% 26 % Expected life 5.5 years 5.5 years LTPP: Volatility of Agilent shares 31% 29% Volatility of selected peer-company shares 22%-84% 23%-81% Pair-wise correlation with selected peers 42% 41% Post-vest holding restriction discount for all executive awards 7.1% 6.5% The fair value of share-based awards for our employee stock option awards was estimated using the Black-Scholes option pricing model. Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For the volatility of our LTPP (TSR) grants, we used our own historical stock price volatility. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value. We use historical volatility to estimate the expected stock price volatility assumption for employee stock option awards. In reaching the conclusion, we have considered many factors including the extent to which our options are currently traded and our ability to find traded options in the current market with similar terms and prices to the options we are valuing. In estimating the expected life of our options granted, we considered the historical option exercise behavior of our executives, which we believe is representative of future behavior. The estimated fair value of restricted stock units and LTPP (EPS) awards is determined based on the market price of our common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (EPS) reflects the cost of awards that are probable to vest at the end of the performance period.

INCOME TAXES (Notes)

INCOME TAXES (Notes)	3 Months Ended
	Jan. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the three months ended January 31, 2023, our income tax expense was $58 million with an effective tax rate of 14.1 percent. Our effective tax rate increased in 2023 compared to 2022, primarily due to the mandatory capitalization of research and development expenses, which became effective for Agilent in the first quarter of 2023, due to a change in tax law from the Tax Cuts and Jobs Act of 2017. For the three months ended January 31, 2023, our effective tax rate and the resulting provision for income taxes were also impacted by the excess tax benefits from stock-based compensation of $12 million along with the expiration of various foreign statutes of limitations which resulted in the recognition of previously unrecognized tax benefits of $7 million. For the three months ended January 31, 2022, our income tax expense was $36 million with an effective tax rate of 11.3 percent. The income taxes for the three months ended January 31, 2022 include the excess tax benefits from stock-based compensation of $16 million. For the three months ended January 31, 2022, our effective tax rate and the resulting provision for income taxes were also impacted by the expiration of various foreign statutes of limitations which resulted in the recognition of previously unrecognized tax benefits of $8 million. In the U.S., tax years remain open back to the year 2018 for federal income tax purposes and for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2013. With these jurisdictions and the U.S., it is reasonably possible there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.

NET INCOME PER SHARE (Notes)

NET INCOME PER SHARE (Notes)	3 Months Ended
	Jan. 31, 2023
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NET INCOME PER SHARE The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended January 31, 2023 2022 (in millions) Numerator: Net income $ 352 $ 283 Denominator: Basic weighted-average shares 296 301 Potential common shares— stock options and other employee stock plans 1 2 Diluted weighted-average shares 297 303 The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value were greater than the average market price of our common stock because their effect would also be anti-dilutive.

INVENTORY (Notes)

INVENTORY (Notes)	3 Months Ended
	Jan. 31, 2023
Inventory, Net [Abstract]
INVENTORY	INVENTORY Inventory as of January 31, 2023 and October 31, 2022 consisted of the following: January 31, October 31, (in millions) Finished goods $ 589 $ 555 Purchased parts and fabricated assemblies 522 483 Inventory $ 1,111 $ 1,038

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)	3 Months Ended
	Jan. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2023: Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2022 $ 1,743 $ 1,953 $ 256 $ 3,952 Foreign currency translation impact 12 1 7 20 Goodwill arising from acquisitions and adjustments — 11 — 11 Goodwill as of January 31, 2023 $ 1,755 $ 1,965 $ 263 $ 3,983 The component parts of other intangible assets as of January 31, 2023 and October 31, 2022 are shown in the table below: Other Intangible Assets Gross Accumulated Net Book (in millions) As of October 31, 2022 Purchased technology $ 1,733 $ 1,068 $ 665 Trademark/Tradename 196 148 48 Customer relationships 180 105 75 Backlog 8 8 — Third-party technology and licenses 32 9 23 Total amortizable intangible assets 2,149 1,338 811 In-Process R&D 10 — 10 Total $ 2,159 $ 1,338 $ 821 As of January 31, 2023 Purchased technology $ 1,761 $ 1,096 $ 665 Trademark/Tradename 196 152 44 Customer relationships 181 113 68 Backlog 8 8 — Third-party technology and licenses 33 10 23 Total amortizable intangible assets 2,179 1,379 800 In-Process R&D 10 — 10 Total $ 2,189 $ 1,379 $ 810 During the three months ended January 31, 2023, we recorded additions to goodwill of $11 million and to other intangible assets of $23 million in our diagnostics and genomics segment related to the acquisition of one business. During the three months ended January 31, 2023, other intangible assets in total increased $2 million due to the impact of foreign currency translation. In general, for U.S. federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three months ended January 31, 2023 and 2022 we did not identify any triggering events or circumstances which would indicate an impairment of goodwill or indefinite-lived intangible assets. Amortization expense of intangible assets was $36 million and $51 million for the three months ended January 31, 2023 and 2022, respectively. Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2023 and for each of the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2023 $ 109 2024 $ 129 2025 $ 104 2026 $ 75 2027 $ 73 2028 $ 67 Thereafter $ 243

FAIR VALUE MEASUREMENTS (Notes)

FAIR VALUE MEASUREMENTS (Notes)	3 Months Ended
	Jan. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2023 were as follows: Fair Value Measurement at January 31, 2023 Using January 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 652 $ 652 $ — $ — Derivative instruments (foreign exchange contracts) 8 — 8 — Long-term Trading securities 36 36 — — Other investments 27 — 27 — Total assets measured at fair value $ 723 $ 688 $ 35 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 28 $ — $ 28 $ — Contingent consideration 2 — — 2 Long-term Deferred compensation liability 36 — 36 — Contingent consideration 1 — — 1 Total liabilities measured at fair value $ 67 $ — $ 64 $ 3 Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2022 were as follows: Fair Value Measurement at October 31, 2022 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 492 $ 492 $ — $ — Derivative instruments (foreign exchange contracts) 31 — 31 — Long-term Trading securities 31 31 — — Other investments 23 — 23 — Total assets measured at fair value $ 577 $ 523 $ 54 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Contingent consideration 66 — — 66 Long-term Deferred compensation liability 31 — 31 — Contingent consideration 1 — — 1 Total liabilities measured at fair value $ 103 $ — $ 36 $ 67 Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. These shares have been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself. Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss) within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income. Gains and losses reflected in other income (expense), net for our equity investments with readily determinable fair value ("RDFV") and equity investments without RDFV are summarized below: Three Months Ended January 31, 2023 2022 (in millions) Net loss recognized during the period on equity securities $ 10 $ 47 Less: Net loss on equity securities sold during the period $ 11 $ — Unrealized (gain) loss on equity securities $ (1) $ 47 Contingent Consideration. The fair value of the contingent consideration liability relates to milestone payments in connection with the acquisition of advanced artificial intelligence technology in February 2022 and the acquisition of Resolution Bioscience in April 2021. Resolution Bioscience . The fair value of the potential future milestone payments, which is set to certain revenue and technical targets, was based on (i) the probability of achieving the relevant revenue targets and technical milestones and (ii) the timing of achieving such milestones, which are significant unobservable inputs, and has been classified as Level 3. We used the Monte Carlo simulation approach to estimate the fair value of the revenue component which resulted in a fair value of zero. A change in any of these unobservable inputs can significantly change the fair value of the contingent consideration. As of January 31, 2023, the expected maximum earn-out period for the contingent payments does not exceed 1.9 years and potential future payments will not exceed $80 million. The contingent consideration liability is our only recurring Level 3 asset or liability. A summary of the Level 3 activity follows: Three Months Ended January 31, 2023 2022 (in millions) Beginning balance $ 67 $ 89 Additions to contingent consideration (including measurement period adjustment) $ — $ — Payments $ (65) $ — Change in fair value (included within selling, general and administrative expenses) $ 1 $ 3 Ending balance $ 3 $ 92 The fair value of the contingent consideration liability as of January 31, 2023, was estimated to be $3 million of which $2 million was recorded in other accrued liabilities and $1 million was recorded in other long-term liabilities on the condensed consolidated balance sheet. During the three months ended January 31, 2023, we made a contingent consideration payment of $65 million related to the achievement of a certain technical milestone associated with our acquisition of Resolution Bioscience. Impairment of Investments. There were no impairments of investments for the three months ended January 31, 2023 and 2022. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis For the three months ended January 31, 2023 and 2022 , there were no impairments of long-lived assets held and used or long-lived assets held for sale. Non-Marketable Equity Securities For the three months ended January 31, 2023 and 2022, there were no impairments or unrealized gain (loss) adjustments to the carrying value of non-marketable securities without readily determinable fair value based on an observable market transaction. As of January 31, 2023, the cumulative net gain (loss) on our non-marketable equity securities without readily determinable fair values was comprised of a $35 million gain and no losses, and the carrying amount was $126 million. As of January 31, 2022, the cumulative net gain (loss) on our non-marketable equity securities without readily determinable fair values was comprised of a $30 million gain and no losses, and the carrying amount was $125 million. Fair values for the non-marketable securities included in long-term investments on the condensed consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when they occur.

DERIVATIVES (Notes)

DERIVATIVES (Notes)	3 Months Ended
	Jan. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES	DERIVATIVES We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts and purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates. Cash Flow Hedges We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of January 31, 2023, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the condensed consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense), net in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense), net in the condensed consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the three months ended January 31, 2023 and 2022, ineffectiveness and gains and losses recognized in other income (expense), net due to de-designation of cash flow hedge contracts were not significant. In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at January 31, 2023 was $3 million. In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019, and we recognized a deferred loss of $6 million in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at January 31, 2023 was $4 million. Net Investment Hedges We enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss)- translation adjustment and are assessed for effectiveness against the underlying exposure every reporting period. If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period. For the three months ended January 31, 2023, ineffectiveness and the resultant effect of any gains or losses recognized in other income (expense) due to de-designation of the hedge contracts were not significant. Other Hedges Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense), net in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities. Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties. A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of January 31, 2023, was $23 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of January 31, 2023. There were 270 foreign exchange forward contracts open as of January 31, 2023, and designated as cash flow hedges. There were 189 foreign exchange forward contracts open as of January 31, 2023, and not designated as hedging instruments. There were 3 foreign exchange forward contracts open as of January 31, 2023, and designated as a net investment hedge. The aggregated notional amounts by currency and designation as of January 31, 2023, were as follows: Derivatives Derivatives Derivatives Forward Forward Forward Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (83) $ (10) $ 25 British Pound (67) — 6 Canadian Dollar (54) — (24) Japanese Yen (89) — (46) Danish Krone — — 22 Korean Won (77) — (7) Singapore Dollar 22 — 14 Chinese Yuan Renminbi (90) — (126) Taiwan Dollar — — (10) Indian Rupee — — (11) Other 4 — 5 Totals $ (434) $ (10) $ (152) Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the condensed consolidated balance sheet as of January 31, 2023, and October 31, 2022, were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location January 31, October 31, 2022 Balance Sheet Location January 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 3 $ 23 Other accrued liabilities $ 19 $ 2 Net investment hedges Foreign exchange contracts Other current assets $ — $ — Other accrued liabilities $ 1 $ — Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 5 $ 8 Other accrued liabilities $ 8 $ 3 Total derivatives $ 8 $ 31 $ 28 $ 5 The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our condensed consolidated statement of operations were as follows: Three Months Ended January 31, 2023 2022 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive loss $ (31) $ 8 Gain (loss) reclassified from accumulated other comprehensive loss into cost of sales $ 6 $ 3 Gain (loss) on time value of forward contracts recorded in cost of sales $ 2 $ — Net Investment Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive loss - translation adjustment $ (1) $ 3 Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ (13) $ (3) At January 31, 2023, the amount of existing net gain that is expected to be reclassified from accumulated other comprehensive income (loss) is $14 million. Within the next twelve months it is estimated that $19 million of loss included within the net amount of accumulated other comprehensive income (loss) will be reclassified to cost of sales in respect of cash flow hedges.

RETIREMENT PLANS AND POST RETIR

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes)	3 Months Ended
	Jan. 31, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Components of net periodic costs (benefits). For the three months ended January 31, 2023 and 2022, our net pension and post retirement benefit costs (benefits) were comprised of the following: Three Months Ended January 31, U.S. Non-U.S. U.S. Post Retirement 2023 2022 2023 2022 2023 2022 (in millions) Service cost—benefits earned during the period $ — $ — $ 6 $ 8 $ — $ — Interest cost on benefit obligation 5 3 6 2 1 1 Expected return on plan assets (5) (6) (9) (11) (1) (1) Amortization: Actuarial losses (gains) — — (1) 6 — (1) Total net plan costs (benefits) $ — $ (3) $ 2 $ 5 $ — $ (1) The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations. Employer contributions and expected future employer contributions for the remainder of the year were as follows: Three Months Ended Employer Contributions January 31, For Remainder of Year 2023 2022 2023 (in millions) U.S. defined benefit plans $ — $ — $ — Non-U.S. defined benefit plans $ 5 $ 5 $ 11

WARRANTIES AND CONTINGENCIES (N

WARRANTIES AND CONTINGENCIES (Notes)	3 Months Ended
	Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
WARRANTIES AND CONTINGENCIES	WARRANTIES AND CONTINGENCIES Warranties We accrue for standard warranty costs based on historical trends in actual warranty charges over the past 12 months. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product. A summary of the standard warranty accrual activity is shown in the table below: Three Months Ended January 31, 2023 2022 (in millions) Standard warranty accrual, beginning balance $ 30 $ 30 Accruals for warranties including change in estimates 11 13 Settlements made during the period (13) (13) Standard warranty accrual, ending balance $ 28 $ 30 Accruals for warranties due within one year $ 28 $ 29 Accruals for warranties due after one year — 1 Standard warranty accrual, ending balance $ 28 $ 30 Bank Guarantees Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $37 million as of both January 31, 2023 and October 31, 2022, respectively. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss. Contingencies We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, condensed consolidated financial condition, results of operations or cash flows.

SHORT-TERM DEBT (Notes)

SHORT-TERM DEBT (Notes)	3 Months Ended
	Jan. 31, 2023
Short-Term Debt [Abstract]
SHORT-TERM DEBT	SHORT-TERM DEBT Credit Facilities On March 13, 2019, we entered into a credit agreement with a group of financial institutions which, as amended, provided for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024 and incremental term loan facilities in an aggregate amount of up to $500 million. On April 21, 2021, we entered into an incremental assumption agreement, pursuant to which the aggregate amount available for borrowing under the revolving credit facility was increased to $1.35 billion and the aggregate amount available for incremental facilities was refreshed to remain at $500 million. As of January 31, 2023, we had no borrowings outstanding under the credit facility and no borrowings under the incremental facilities. We were in compliance with the covenants for the credit facility during the three months ended January 31, 2023. Commercial Paper Under our U.S. commercial paper program, the company may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.35 billion with up to 397-day maturities. At any point in time, the company intends to maintain available commitments under its revolving credit facility in an amount at least equal to the amount of the commercial paper notes outstanding. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The proceeds from issuances under the program may be used for general corporate purposes. During the three months ended January 31, 2023, we borrowed $527 million and repaid $324 million. As of January 31, 2023 , we had borrowings of $238 million outstanding under our U.S. commercial paper program and had a weighted average annual interest rate of 4.67 percent.

LONG-TERM DEBT (Notes)

LONG-TERM DEBT (Notes)	3 Months Ended
	Jan. 31, 2023
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT Term Loan Facility On April 15, 2022, we entered into a term loan agreement with a group of financial institutions, which provided for a $600 million delayed draw term loan that will mature on April 15, 2025. As of January 31, 2023, we had $600 million borrowings outstanding under the term loan facility and had a weighted average interest rate of 5.40 percent. Loans under the term loan agreement bear interest, at our option, either at: (i) the alternate base rate, as defined in the term loan agreement, plus the applicable margin for such loans or (ii) adjusted term SOFR, as defined in the term loan agreement, plus the applicable margin for such loans. The term loan agreement contains customary representations and warranties as well as customary affirmative and negative covenants. We were in compliance with the covenants for the term loan during the three months ended January 31, 2023. Senior Notes The following table summarizes the company’s long-term senior notes: January 31, 2023 October 31, 2022 Amortized Amortized (in millions) 2026 Senior Notes 299 299 2029 Senior Notes 495 495 2030 Senior Notes 496 496 2031 Senior Notes 843 843 Total Senior Notes $ 2,133 $ 2,133

STOCKHOLDERS' EQUITY (Notes)

STOCKHOLDERS' EQUITY (Notes)	3 Months Ended
	Jan. 31, 2023
Stockholders' Equity Note [Abstract]
STOCKHOLDERS EQUITY	STOCKHOLDERS' EQUITY Stock Repurchase Program On February 16, 2021 we announced that our board of directors had approved a new share repurchase program (the "2021 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2021 repurchase program authorizes the purchase of up to $2.0 billion of our common stock at the company's discretion and has no fixed termination date. The 2021 repurchase program which became effective on February 18, 2021, replaced and terminated the 2019 repurchase program on that date. The 2021 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the three months ended January 31, 2023, we repurchased and retired 499,000 shares for $75 million under this authorization. During the three months ended January 31, 2022, we repurchased and retired 2.9 million shares for $447 million under this authorization. As of January 31, 2023, we had remaining authorization to repurchase up to approximately $363 million of our common stock under the 2021 repurchase program. On March 1, 2023, the 2021 repurchase program was terminated and the remaining authorization of $339 million expired. On January 9, 2023, we announced that our board of directors had approved a share repurchase program (the "2023 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2023 repurchase program authorizes the purchase of up to $2.0 billion of our common stock at the company's discretion and has no fixed termination date. The 2023 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. The 2023 repurchase program commenced on March 1, 2023, and also terminated and replaced the 2021 repurchase program. Cash Dividends on Shares of Common Stock During the three months ended January 31, 2023, we paid cash dividends of $0.225 per common share or $67 million on the company's common stock. During the three months ended January 31, 2022, we paid cash dividends of $0.210 per common share or $63 million on the company's common stock. On February 22, 2023, our board of directors declared a quarterly dividend of $0.225 per share of common stock or approximately $67 million which will be paid on April 26, 2023 to all shareholders of record at the close of business on April 4, 2023. The timing and amounts of any future dividends are subject to determination and approval by our board of directors. Accumulated Other Comprehensive Income (Loss) Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended January 31, 2023 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of October 31, 2022 $ (335) $ 123 $ (155) $ 20 $ (347) Other comprehensive income (loss) before reclassifications 90 — 3 (31) 62 Amounts reclassified out of accumulated other comprehensive income (loss) — — (1) (6) (7) Tax benefit 1 — — 11 12 Other comprehensive income (loss) 91 — 2 (26) 67 As of January 31, 2023 $ (244) $ 123 $ (153) $ (6) $ (280) Reclassifications out of accumulated other comprehensive income (loss) for the three months ended January 31, 2023 and 2022 were as follows (in millions): Details about accumulated other Amounts Reclassified from Affected line item in Three Months Ended January 31, 2023 2022 Unrealized gain on derivatives $ 6 $ 3 Cost of products 6 3 Total before income tax (2) (1) Provision for income tax 4 2 Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net gain (loss) 1 (6) Other income (expense) 1 (6) Total before income tax (1) 1 (Provision) benefit for income tax — (5) Total net of income tax Total reclassifications for the period $ 4 $ (3) Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss). Reclassifications out of accumulated other comprehensive income (loss) of actuarial net gain (loss) in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 11, "Retirement Plans and Post Retirement Pension Plans").

SEGMENT INFORMATION (Notes)

SEGMENT INFORMATION (Notes)	3 Months Ended
	Jan. 31, 2023
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Description of segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. We continue to have three business segments comprised of life sciences and applied markets, diagnostics and genomics and Agilent CrossLab, each of which continues to comprise a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments. A description of our three reportable segments is as follows: Our life sciences and applied markets business provides application-focused solutions that include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies. Our consumables portfolio is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries to supplies. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business is a contract and development manufacturing organization that provides services related to and the production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in a class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential tissue and liquid-based pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business provides clinical flow cytometry reagents for routine cancer diagnostics. This business also provides bulk antibodies as raw materials and associated assay development services to IVD manufacturers, biotechnology and pharmaceutical companies. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples. Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques including NGS, utilized in clinical and life science research applications. The Agilent CrossLab business spans the entire lab with its extensive services portfolio, which is designed to improve customer outcomes. The majority of the portfolio is vendor neutral, meaning we can serve and supply customers regardless of their instrument purchase choices. The services portfolio include repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and various other custom services to support the customers' laboratory operations. Custom services are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses, costs of centralized research and development and joint sales and marketing costs. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate asset impairments, amortization of acquisition-related intangible assets, change in the fair value of acquisition-related contingent consideration, acquisition and integration costs, transformational initiatives expenses, business exit and divestiture costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities. The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments. The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below: Three Months Ended January 31, 2023 2022 (in millions) Net Revenue: Life Sciences and Applied Markets $ 1,033 $ 976 Diagnostics and Genomics 342 339 Agilent CrossLab 381 359 Total net revenue $ 1,756 $ 1,674 Segment Income From Operations: Life Sciences and Applied Markets $ 314 $ 282 Diagnostics and Genomics 59 68 Agilent CrossLab 103 91 Total segment income from operations $ 476 $ 441 The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes: Three Months Ended January 31, 2023 2022 (in millions) Total segment income from operations $ 476 $ 441 Transformational initiatives (7) (4) Amortization of intangible assets related to business combinations (36) (51) Acquisition and integration costs (2) (7) Change in fair value of contingent consideration (1) (3) Other (4) — Interest income 9 1 Interest expense (25) (21) Other income (expense), net (1) — (37) Income before taxes, as reported $ 410 $ 319 (1) For the three months ended January 31, 2023 and 2022, other income (expense), net includes net (gains) losses on the fair value of equity securities. The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, short-term and long-term investments, deferred tax assets, right-of-use assets and other assets. January 31, October 31, (in millions) Segment Assets: Life Sciences and Applied Markets $ 4,004 $ 3,955 Diagnostics and Genomics 3,520 3,489 Agilent CrossLab 962 869 Total segment assets $ 8,486 $ 8,313

OVERVIEW, BASIS OF PRESENTATI_2

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
Overview and Basis of Presentation	Overview. Agilent Technologies, Inc. ("we," "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three months ended January 31, 2023 and 2022 pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2022 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2022. In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of January 31, 2023 and October 31, 2022, condensed consolidated statement of comprehensive income (loss) for the three months ended January 31, 2023 and 2022, condensed consolidated statement of operations for the three months ended January 31, 2023 and 2022, condensed consolidated statement of cash flows for the three months ended January 31, 2023 and 2022 and condensed consolidated statement of equity for the three months ended January 31, 2023 and 2022.
Use of Estimates	Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement benefit plan assumptions and accounting for income taxes.
Restricted Cash and Restricted Cash Equivalents	Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows: January 31, October 31, 2023 2022 (in millions) Cash and cash equivalents $ 1,250 $ 1,053 Restricted cash included in other assets 3 3 Total cash, cash equivalents and restricted cash $ 1,253 $ 1,056
Leases	Leases. As of January 31, 2023 and October 31, 2022, operating lease right-of-use assets where we are the lessee were $ 155 million 150 million 159 million 152 million
Variable Interest Entity	Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of January 31, 2023 and October 31, 2022, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value ("RDFV"), depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of January 31, 2023 and October 31, 2022, the total carrying value of investments and loans in privately held companies considered as VIEs was $71 million and $87 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the condensed consolidated balance sheet.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. As of January 31, 2023 and October 31, 2022, the fair value of the term loans approximates its carrying value. As of January 31, 2023, the fair value of our senior notes was $1,859 million with a carrying value of $2,133 million. This compares to the fair value of our senior notes of $1,754 million with a carrying value of $2,133 million as of October 31, 2022. The change in the fair value compared to carrying value in the three months ended January 31, 2023 is primarily due to decreased market interest rates. The fair value was calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments and contingent consideration.

OVERVIEW, BASIS OF PRESENTATI_3

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Jan. 31, 2023
Restricted Cash [Abstract]
Restrictions on Cash and Cash Equivalents	Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows: January 31, October 31, 2023 2022 (in millions) Cash and cash equivalents $ 1,250 $ 1,053 Restricted cash included in other assets 3 3 Total cash, cash equivalents and restricted cash $ 1,253 $ 1,056

REVENUE (Tables)

REVENUE (Tables)	3 Months Ended
	Jan. 31, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Three Months Ended January 31, 2023 2022 Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total (in millions) Revenue by Region Americas $ 332 $ 154 $ 201 $ 687 $ 317 $ 132 $ 188 $ 637 Europe 259 98 99 456 252 98 101 451 Asia Pacific 442 129 42 613 407 129 50 586 Total $ 1,033 $ 381 $ 342 $ 1,756 $ 976 $ 359 $ 339 $ 1,674 The following table presents the company’s total revenue disaggregated by end markets and by revenue type: Three Months Ended January 31, 2023 2022 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 639 $ 602 Chemicals and Advanced Materials 406 373 Diagnostics and Clinical 239 243 Food 160 158 Academia and Government 146 141 Environmental and Forensics 166 157 Total $ 1,756 $ 1,674 Revenue by Type Instrumentation $ 759 $ 691 Non-instrumentation and other 997 983 Total $ 1,756 $ 1,674
Contract Liabilities and Changes in Balances	The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2023: Contract (in millions) Ending balance as of October 31, 2022 $ 557 Net revenue deferred in the period 246 Revenue recognized that was included in the contract liability balance at the beginning of the period (196) Change in deferrals from customer cash advances, net of revenue recognized (5) Currency translation and other adjustments 21 Ending balance as of January 31, 2023 $ 623

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Jan. 31, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Allocated share-based compensation expense disclosure	The impact on our results for share-based compensation was as follows: Three Months Ended January 31, 2023 2022 (in millions) Cost of products and services $ 13 $ 11 Research and development 5 6 Selling, general and administrative 26 28 Total share-based compensation expense $ 44 $ 45
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Text Block]	The following assumptions were used to estimate the fair value of awards granted. Three Months Ended January 31, 2023 2022 Stock Option Plans: Weighted average risk-free interest rate 3.9% 1.3 % Dividend yield 0.6% 0.5 % Weighted average volatility 28% 26 % Expected life 5.5 years 5.5 years LTPP: Volatility of Agilent shares 31% 29% Volatility of selected peer-company shares 22%-84% 23%-81% Pair-wise correlation with selected peers 42% 41% Post-vest holding restriction discount for all executive awards 7.1% 6.5%

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	3 Months Ended
	Jan. 31, 2023
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators of the basic and diluted net income per share	The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended January 31, 2023 2022 (in millions) Numerator: Net income $ 352 $ 283 Denominator: Basic weighted-average shares 296 301 Potential common shares— stock options and other employee stock plans 1 2 Diluted weighted-average shares 297 303

INVENTORY (Tables)

INVENTORY (Tables)	3 Months Ended
	Jan. 31, 2023
Inventory, Net [Abstract]
INVENTORY	INVENTORY Inventory as of January 31, 2023 and October 31, 2022 consisted of the following: January 31, October 31, (in millions) Finished goods $ 589 $ 555 Purchased parts and fabricated assemblies 522 483 Inventory $ 1,111 $ 1,038

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Jan. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill balances and movements for each reportable segment during the period	The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2023: Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2022 $ 1,743 $ 1,953 $ 256 $ 3,952 Foreign currency translation impact 12 1 7 20 Goodwill arising from acquisitions and adjustments — 11 — 11 Goodwill as of January 31, 2023 $ 1,755 $ 1,965 $ 263 $ 3,983
Components of other intangible assets during the period	The component parts of other intangible assets as of January 31, 2023 and October 31, 2022 are shown in the table below: Other Intangible Assets Gross Accumulated Net Book (in millions) As of October 31, 2022 Purchased technology $ 1,733 $ 1,068 $ 665 Trademark/Tradename 196 148 48 Customer relationships 180 105 75 Backlog 8 8 — Third-party technology and licenses 32 9 23 Total amortizable intangible assets 2,149 1,338 811 In-Process R&D 10 — 10 Total $ 2,159 $ 1,338 $ 821 As of January 31, 2023 Purchased technology $ 1,761 $ 1,096 $ 665 Trademark/Tradename 196 152 44 Customer relationships 181 113 68 Backlog 8 8 — Third-party technology and licenses 33 10 23 Total amortizable intangible assets 2,179 1,379 800 In-Process R&D 10 — 10 Total $ 2,189 $ 1,379 $ 810
Schedule of estimated future amortization expense of finite-lived intangible assets	Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2023 and for each of the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2023 $ 109 2024 $ 129 2025 $ 104 2026 $ 75 2027 $ 73 2028 $ 67 Thereafter $ 243

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Jan. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Assets And Liabilities Measured On Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2023 were as follows: Fair Value Measurement at January 31, 2023 Using January 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 652 $ 652 $ — $ — Derivative instruments (foreign exchange contracts) 8 — 8 — Long-term Trading securities 36 36 — — Other investments 27 — 27 — Total assets measured at fair value $ 723 $ 688 $ 35 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 28 $ — $ 28 $ — Contingent consideration 2 — — 2 Long-term Deferred compensation liability 36 — 36 — Contingent consideration 1 — — 1 Total liabilities measured at fair value $ 67 $ — $ 64 $ 3 Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2022 were as follows: Fair Value Measurement at October 31, 2022 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 492 $ 492 $ — $ — Derivative instruments (foreign exchange contracts) 31 — 31 — Long-term Trading securities 31 31 — — Other investments 23 — 23 — Total assets measured at fair value $ 577 $ 523 $ 54 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Contingent consideration 66 — — 66 Long-term Deferred compensation liability 31 — 31 — Contingent consideration 1 — — 1 Total liabilities measured at fair value $ 103 $ — $ 36 $ 67
Gain (Loss) on Securities	Gains and losses reflected in other income (expense), net for our equity investments with readily determinable fair value ("RDFV") and equity investments without RDFV are summarized below: Three Months Ended January 31, 2023 2022 (in millions) Net loss recognized during the period on equity securities $ 10 $ 47 Less: Net loss on equity securities sold during the period $ 11 $ — Unrealized (gain) loss on equity securities $ (1) $ 47
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The contingent consideration liability is our only recurring Level 3 asset or liability. A summary of the Level 3 activity follows: Three Months Ended January 31, 2023 2022 (in millions) Beginning balance $ 67 $ 89 Additions to contingent consideration (including measurement period adjustment) $ — $ — Payments $ (65) $ — Change in fair value (included within selling, general and administrative expenses) $ 1 $ 3 Ending balance $ 3 $ 92

DERIVATIVES (Tables)

DERIVATIVES (Tables)	3 Months Ended
	Jan. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregated notional amounts by currency and designation	The aggregated notional amounts by currency and designation as of January 31, 2023, were as follows: Derivatives Derivatives Derivatives Forward Forward Forward Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (83) $ (10) $ 25 British Pound (67) — 6 Canadian Dollar (54) — (24) Japanese Yen (89) — (46) Danish Krone — — 22 Korean Won (77) — (7) Singapore Dollar 22 — 14 Chinese Yuan Renminbi (90) — (126) Taiwan Dollar — — (10) Indian Rupee — — (11) Other 4 — 5 Totals $ (434) $ (10) $ (152)
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet	Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the condensed consolidated balance sheet as of January 31, 2023, and October 31, 2022, were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location January 31, October 31, 2022 Balance Sheet Location January 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 3 $ 23 Other accrued liabilities $ 19 $ 2 Net investment hedges Foreign exchange contracts Other current assets $ — $ — Other accrued liabilities $ 1 $ — Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 5 $ 8 Other accrued liabilities $ 8 $ 3 Total derivatives $ 8 $ 31 $ 28 $ 5
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations	The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our condensed consolidated statement of operations were as follows: Three Months Ended January 31, 2023 2022 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive loss $ (31) $ 8 Gain (loss) reclassified from accumulated other comprehensive loss into cost of sales $ 6 $ 3 Gain (loss) on time value of forward contracts recorded in cost of sales $ 2 $ — Net Investment Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive loss - translation adjustment $ (1) $ 3 Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ (13) $ (3)

RETIREMENT PLANS AND POST RET_2

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	3 Months Ended
	Jan. 31, 2023
Defined Benefit Plan, Net Periodic Benefit Cost
Schedule of net pension and post-retirement benefit costs	Components of net periodic costs (benefits). For the three months ended January 31, 2023 and 2022, our net pension and post retirement benefit costs (benefits) were comprised of the following: Three Months Ended January 31, U.S. Non-U.S. U.S. Post Retirement 2023 2022 2023 2022 2023 2022 (in millions) Service cost—benefits earned during the period $ — $ — $ 6 $ 8 $ — $ — Interest cost on benefit obligation 5 3 6 2 1 1 Expected return on plan assets (5) (6) (9) (11) (1) (1) Amortization: Actuarial losses (gains) — — (1) 6 — (1) Total net plan costs (benefits) $ — $ (3) $ 2 $ 5 $ — $ (1) The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.
Employer Contributions and Expected Employer Contributions	Employer contributions and expected future employer contributions for the remainder of the year were as follows: Three Months Ended Employer Contributions January 31, For Remainder of Year 2023 2022 2023 (in millions) U.S. defined benefit plans $ — $ — $ — Non-U.S. defined benefit plans $ 5 $ 5 $ 11

WARRANTIES AND CONTINGENCIES (T

WARRANTIES AND CONTINGENCIES (Table)	3 Months Ended
	Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Standard warranty	A summary of the standard warranty accrual activity is shown in the table below: Three Months Ended January 31, 2023 2022 (in millions) Standard warranty accrual, beginning balance $ 30 $ 30 Accruals for warranties including change in estimates 11 13 Settlements made during the period (13) (13) Standard warranty accrual, ending balance $ 28 $ 30 Accruals for warranties due within one year $ 28 $ 29 Accruals for warranties due after one year — 1 Standard warranty accrual, ending balance $ 28 $ 30

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	3 Months Ended
	Jan. 31, 2023
Debt Disclosure [Abstract]
Schedule of Senior Notes	The following table summarizes the company’s long-term senior notes: January 31, 2023 October 31, 2022 Amortized Amortized (in millions) 2026 Senior Notes 299 299 2029 Senior Notes 495 495 2030 Senior Notes 496 496 2031 Senior Notes 843 843 Total Senior Notes $ 2,133 $ 2,133

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Jan. 31, 2023
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended January 31, 2023 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of October 31, 2022 $ (335) $ 123 $ (155) $ 20 $ (347) Other comprehensive income (loss) before reclassifications 90 — 3 (31) 62 Amounts reclassified out of accumulated other comprehensive income (loss) — — (1) (6) (7) Tax benefit 1 — — 11 12 Other comprehensive income (loss) 91 — 2 (26) 67 As of January 31, 2023 $ (244) $ 123 $ (153) $ (6) $ (280)
Reclassification out of Accumulated Other Comprehensive Income	Reclassifications out of accumulated other comprehensive income (loss) for the three months ended January 31, 2023 and 2022 were as follows (in millions): Details about accumulated other Amounts Reclassified from Affected line item in Three Months Ended January 31, 2023 2022 Unrealized gain on derivatives $ 6 $ 3 Cost of products 6 3 Total before income tax (2) (1) Provision for income tax 4 2 Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net gain (loss) 1 (6) Other income (expense) 1 (6) Total before income tax (1) 1 (Provision) benefit for income tax — (5) Total net of income tax Total reclassifications for the period $ 4 $ (3)

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
	Jan. 31, 2023
Segment Reporting [Abstract]
Segment Profitability and Segment Assets	The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below: Three Months Ended January 31, 2023 2022 (in millions) Net Revenue: Life Sciences and Applied Markets $ 1,033 $ 976 Diagnostics and Genomics 342 339 Agilent CrossLab 381 359 Total net revenue $ 1,756 $ 1,674 Segment Income From Operations: Life Sciences and Applied Markets $ 314 $ 282 Diagnostics and Genomics 59 68 Agilent CrossLab 103 91 Total segment income from operations $ 476 $ 441 The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, short-term and long-term investments, deferred tax assets, right-of-use assets and other assets. January 31, October 31, (in millions) Segment Assets: Life Sciences and Applied Markets $ 4,004 $ 3,955 Diagnostics and Genomics 3,520 3,489 Agilent CrossLab 962 869 Total segment assets $ 8,486 $ 8,313
Reconciliation of segment results to total enterprise results	The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes: Three Months Ended January 31, 2023 2022 (in millions) Total segment income from operations $ 476 $ 441 Transformational initiatives (7) (4) Amortization of intangible assets related to business combinations (36) (51) Acquisition and integration costs (2) (7) Change in fair value of contingent consideration (1) (3) Other (4) — Interest income 9 1 Interest expense (25) (21) Other income (expense), net (1) — (37) Income before taxes, as reported $ 410 $ 319 (1) For the three months ended January 31, 2023 and 2022, other income (expense), net includes net (gains) losses on the fair value of equity securities.

OVERVIEW, BASIS OF PRESENTATI_4

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	Jan. 31, 2023	Oct. 31, 2022	Jan. 31, 2022	Oct. 31, 2021
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cash and cash equivalents	$ 1,250	$ 1,053
Restricted Cash	3	3
Cash, cash equivalents, restricted cash and restricted cash equivalents	1,253	1,056	$ 1,116	$ 1,490
Operating Leases
Right-of-Use Asset	$ 155	$ 150
Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Operating lease liability	$ 159	$ 152
Operating Lease Liability, Statement of Financial Position [Extensible Enumeration]	Other accrued liabilities, Other long-term liabilities	Other accrued liabilities, Other long-term liabilities
Fair Value of Financial Instruments
Carrying Value of Senior Notes	$ 2,133	$ 2,133
Variable Interest Entity
Assets	10,919	10,532
Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes
Fair Value of Financial Instruments
Fair Value of Senior Notes	1,859	1,754
Variable Interest Entity, Not Primary Beneficiary [Member]
Variable Interest Entity
Assets	$ 71	$ 87

REVENUE- Revenue by Region (Det

REVENUE- Revenue by Region (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Net revenue	$ 1,756	$ 1,674
Life Sciences and Applied Markets
Net revenue	1,033	976
Agilent CrossLab
Net revenue	381	359
Diagnostics and Genomics
Net revenue	342	339
Americas
Net revenue	687	637
Americas | Life Sciences and Applied Markets
Net revenue	332	317
Americas | Agilent CrossLab
Net revenue	154	132
Americas | Diagnostics and Genomics
Net revenue	201	188
Europe
Net revenue	456	451
Europe | Life Sciences and Applied Markets
Net revenue	259	252
Europe | Agilent CrossLab
Net revenue	98	98
Europe | Diagnostics and Genomics
Net revenue	99	101
Asia Pacific
Net revenue	613	586
Asia Pacific | Life Sciences and Applied Markets
Net revenue	442	407
Asia Pacific | Agilent CrossLab
Net revenue	129	129
Asia Pacific | Diagnostics and Genomics
Net revenue	$ 42	$ 50

REVENUE - Revenue by End Market

REVENUE - Revenue by End Markets (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Net revenue	$ 1,756	$ 1,674
Pharmaceutical and Biopharmaceutical
Net revenue	639	602
Chemical and Advanced Materials
Net revenue	406	373
Diagnostics and Clinical
Net revenue	239	243
Food
Net revenue	160	158
Academia and Government
Net revenue	146	141
Environmental and Forensics
Net revenue	$ 166	$ 157

REVENUE - Revenue by Type (Deta

REVENUE - Revenue by Type (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Net revenue	$ 1,756	$ 1,674
Instrumentation
Net revenue	759	691
Non-Instrumentation and Other
Net revenue	$ 997	$ 983

REVENUE - Contract Assets and L

REVENUE - Contract Assets and Liability (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Oct. 31, 2022
Contract Asset
Contract Assets (Unbilled Accounts Receivable)	$ 276		$ 275
Contract Liability
Contract liability ending balance as of October 31, 2022	557
Net revenue deferred in the period	246
Revenue recognized that was included in the contract liability balance at the beginning of the period	(196)	$ (191)
Change in deferrals from customer cash advances, net of revenue recognized	(5)
Currency Translation and Other Adjustment	21
Contract liability ending balance as of January 31, 2023	$ 623

REVENUE - Remaining Performance

REVENUE - Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-31 $ in Millions	Jan. 31, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation expected timing of satisfaction period	12 months
Remaining performance obligation amount	$ 378

SHARE-BASED COMPENSATION Text (

SHARE-BASED COMPENSATION Text (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Oct. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award
ESPP plan purchase price (in hundredths)	85%	85%
Inventory
Share-based Compensation Arrangement by Share-based Payment Award
Share-based compensation capitalized in inventory	$ 0		$ 0
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage	25%	25%
Vesting Period	4 years	4 years
Maximum contractual term, Expiration Period	10 years	10 years
Exercise Price of Common Stock, Percent of FMV	100%	100%
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage	25%	25%
Vesting Period	4 years	4 years
Minimum | Performance Shares [LTPP]
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage	0%	0%
Maximum | Performance Shares [LTPP]
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage	200%	200%

SHARE-BASED COMPENSATION Alloca

SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Share-based compensation expense	$ 44	$ 45
Cost of Products and Services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Share-based compensation expense	13	11
Research and Development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Share-based compensation expense	5	6
Selling, General and Administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Share-based compensation expense	$ 26	$ 28

SHARE-BASED COMPENSATION Fair V

SHARE-BASED COMPENSATION Fair Value Assumptions (Details)	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average risk-free interest rate	3.90%	1.30%
Dividend yield	0.60%	0.50%
Weighted average volatility	28%	26%
Expected Life	5 years 6 months	5 years 6 months
LTPP
Share-based Compensation Arrangement by Share-based Payment Award
Volatility of Agilent shares	31%	29%
Volatility of selected peer-company shares - Minimum	22%	23%
Volatility of selected peer-company shares - Maximum	84%	81%
Pair-wise correlation with selected peers (in hundredths)	42%	41%
LTPP & RSU
Share-based Compensation Arrangement by Share-based Payment Award
Post-vest holding restriction discount for all executive awards	7.10%	6.50%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Income Tax Disclosure
Provision (benefit) for income taxes	$ 58	$ 36
Effective income tax rate	14.10%	11.30%
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations	$ 7	$ 8
Share-based Payment Arrangement, Expense, Tax Benefit	$ 12	$ 16

NET INCOME PER SHARE (Details)

NET INCOME PER SHARE (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Numerator:
Net income	$ 352	$ 283
Denominators:
Basic weighted-average shares	296	301
Potential common shares - stock options and other employee stock plans	1	2
Diluted weighted average shares	297	303
Anti-dilutive shares excluded from computation of dilutive earnings per share (in shares)	0	0

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Millions	Jan. 31, 2023	Oct. 31, 2022
Inventory, Net [Abstract]
Finished goods	$ 589	$ 555
Purchased parts and fabricated assemblies	522	483
Inventory	$ 1,111	$ 1,038

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Goodwill [Line Items]
Goodwill impairment	$ 0	$ 0
Goodwill Roll Forward
Goodwill beginning balance	3,952
Foreign currency translation impact	20
Goodwill arising from acquisitions	11
Goodwill ending balance	3,983
Life Sciences and Applied Markets
Goodwill Roll Forward
Goodwill beginning balance	1,743
Foreign currency translation impact	12
Goodwill arising from acquisitions	0
Goodwill ending balance	1,755
Diagnostics and Genomics
Goodwill Roll Forward
Goodwill beginning balance	1,953
Foreign currency translation impact	1
Goodwill arising from acquisitions	11
Goodwill ending balance	1,965
Agilent CrossLab
Goodwill Roll Forward
Goodwill beginning balance	256
Foreign currency translation impact	7
Goodwill arising from acquisitions	0
Goodwill ending balance	$ 263

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) - USD ($) $ in Millions	Jan. 31, 2023	Oct. 31, 2022
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	$ 2,179	$ 2,149
Total Intangible Assets	2,189	2,159
Accumulated Amortization	1,379	1,338
Net Book Value	810	821
Finite-Lived Intangible Assets, Net	800	811
Purchased Technology
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	1,761	1,733
Accumulated Amortization	1,096	1,068
Net Book Value	665	665
Trademark/Tradenames
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	196	196
Accumulated Amortization	152	148
Net Book Value	44	48
Customer Relationships
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	181	180
Accumulated Amortization	113	105
Net Book Value	68	75
Backlog
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	8	8
Accumulated Amortization	8	8
Net Book Value	0	0
Third-Party Technology and Licenses
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	33	32
Accumulated Amortization	10	9
Net Book Value	23	23
In-Process R&D
Indefinite-Lived Intangible Assets (Excluding Goodwill)
In-Process R&D	$ 10	$ 10

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Finite-Lived Intangible Assets
Additions to goodwill	$ 11
Addition to other intangible assets	23
Foreign currency translation impact on other intangible assets	2
Goodwill impairment	0	$ 0
Impairment of IPR&D	0	0
Amortization of intangible assets during the period	36	$ 51
Life Sciences and Applied Markets
Finite-Lived Intangible Assets
Additions to goodwill	0
Diagnostics and Genomics
Finite-Lived Intangible Assets
Additions to goodwill	11
Agilent CrossLab
Finite-Lived Intangible Assets
Additions to goodwill	$ 0

GOODWILL AND OTHER INTANGIBLE_6

GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details) $ in Millions	Jan. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2023	$ 109
2024	129
2025	104
2026	75
2027	73
2028	67
Thereafter	$ 243

FAIR VALUE MEASUREMENTS, Fair v

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($) $ in Millions	Jan. 31, 2023	Oct. 31, 2022	Jan. 31, 2022	Oct. 31, 2021
Liabilities
Contingent Consideration	$ 3	$ 67	$ 92	$ 89
Fair Value, Measurements, Recurring
Assets
Total assets measured at fair value	723	577
Liabilities
Total liabilities measured at fair value	67	103
Fair Value, Measurements, Recurring | Other Current Assets
Assets
Cash equivalents (money market funds)	652	492
Derivative instruments (foreign exchange contracts)	8	31
Fair Value, Measurements, Recurring | Other assets
Assets
Trading securities	36	31
Other investments	27	23
Fair Value, Measurements, Recurring | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	28	5
Contingent Consideration	2	66
Fair Value, Measurements, Recurring | Other long-term liabilities
Liabilities
Deferred compensation liability	36	31
Contingent Consideration	1	1
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets
Total assets measured at fair value	688	523
Liabilities
Total liabilities measured at fair value	0	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets
Assets
Cash equivalents (money market funds)	652	492
Derivative instruments (foreign exchange contracts)	0	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets
Assets
Trading securities	36	31
Other investments	0	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	0	0
Contingent Consideration	0	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities
Liabilities
Deferred compensation liability	0	0
Contingent Consideration	0	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Assets
Total assets measured at fair value	35	54
Liabilities
Total liabilities measured at fair value	64	36
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Assets
Assets
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	8	31
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other assets
Assets
Trading securities	0	0
Other investments	27	23
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	28	5
Contingent Consideration	0	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other long-term liabilities
Liabilities
Deferred compensation liability	36	31
Contingent Consideration	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Assets
Total assets measured at fair value	0	0
Liabilities
Total liabilities measured at fair value	3	67
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Assets
Assets
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other assets
Assets
Trading securities	0	0
Other investments	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities | Resolution Bioscience, Inc.
Liabilities
Contingent Consideration	2	66
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities
Liabilities
Deferred compensation liability	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities | Resolution Bioscience, Inc.
Liabilities
Contingent Consideration	$ 1	$ 1

FAIR VALUE MEASUREMENTS - Equit

FAIR VALUE MEASUREMENTS - Equity Securities and Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Fair Value Disclosures [Abstract]
Net (gain) loss on equity securities	$ 10	$ 47
Equity Securities, FV-NI, Realized Gain (Loss)	11	0
Unrealized gain (loss) on equity securities	(1)	47
Impairment of Investments	$ 0	$ 0

FAIR VALUE MEASUREMENTS, Contin

FAIR VALUE MEASUREMENTS, Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jan. 31, 2022	Oct. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value of contingent consideration	$ 3	$ 67	$ 92	$ 89
Resolution Bioscience, Inc.
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Consideration maximum earn-out period	1 year 10 months 24 days
Contingent Consideration Arrangement - Maximum	$ 80
Resolution Bioscience, Inc. | Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Revenue Component
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value of contingent consideration	$ 0

FAIR VALUE MEASUREMENTS - Recon

FAIR VALUE MEASUREMENTS - Reconciliation of Beginning and Ending Level 3 Contingent Consideration Liability (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Contingent Consideration, Beginning Balance	$ 67	$ 89
Additions to contingent consideration (including measurement period adjustment)	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	(65)	0
Change in fair value (included within SG&A)	1	3
Fair Value Contingent Consideration, Ending Balance	$ 3	$ 92

FAIR VALUE MEASUREMENTS, Assets

FAIR VALUE MEASUREMENTS, Assets and Liabilities measured at Fair Value on a Non-Recurring Basis (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Long-Lived Assets
Impairment of Long-Lived Assets Held-for-use	$ 0	$ 0
Impairment of Long-Lived assets Held for sale	$ 0	$ 0

FAIR VALUE MEASUREMENTS, Non Ma

FAIR VALUE MEASUREMENTS, Non Marketable Securities (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Fair Value Disclosures [Abstract]
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount	$ 0	$ 0
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount	0	0
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount	0	0
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount	35	30
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount	0	0
Non-marketable equity securities carrying amount	$ 126	$ 125

DERIVATIVES- Text (Details)

DERIVATIVES- Text (Details) $ in Millions			3 Months Ended
	Sep. 06, 2019 USD ($)	Sep. 15, 2016 USD ($)	Jan. 31, 2023 USD ($)	Aug. 16, 2019 USD ($)	Feb. 01, 2016 USD ($) contracts
Derivative Instruments and Hedging Activities Disclosure
Aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position			$ 23
Senior Notes 2026 | Interest Rate Swap | Derivatives Designated as Hedging Instrument | Cash Flow Hedging
Terminated Derivative Contracts
Number of interest rate swap contracts terminated | contracts					3
Derivative, Notional Amount					$ 300
Remaining Gain (Loss) Reclassification from Accumulated OCI to be amortized to Income,		$ 10	3
Senior Notes 2029 | Treasury Lock [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging
Terminated Derivative Contracts
Derivative, Notional Amount				$ 250
Remaining Gain (Loss) Reclassification from Accumulated OCI to be amortized to Income,	$ 6		$ 4

DERIVATIVES- Foreign Exchange F

DERIVATIVES- Foreign Exchange Forward Contracts (Details) $ in Millions	Jan. 31, 2023 USD ($) contracts
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Forward
Derivative
Number of foreign exchange forward contracts (in units) | contracts	270
Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Foreign Exchange Forward
Derivative
Number of foreign exchange forward contracts (in units) | contracts	3
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Forward
Derivative
Number of foreign exchange forward contracts (in units) | contracts	189
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Forward Contracts USD
Derivative
Derivative, Notional Amount	$ 434
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Euro | Forward Contracts USD
Derivative
Derivative, Notional Amount	83
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | British Pound | Forward Contracts USD
Derivative
Derivative, Notional Amount	67
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Canadian Dollar | Forward Contracts USD
Derivative
Derivative, Notional Amount	54
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Japanese Yen | Forward Contracts USD
Derivative
Derivative, Notional Amount	89
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Korean Won | Forward Contracts USD
Derivative
Derivative, Notional Amount	77
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Chinese Yuan Renminbi | Forward Contracts USD
Derivative
Derivative, Notional Amount	90
Sell | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Forward Contracts USD
Derivative
Derivative, Notional Amount	10
Sell | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Euro | Forward Contracts USD
Derivative
Derivative, Notional Amount	10
Sell | Derivatives Not Designated as Hedging Instruments | Forward Contracts USD
Derivative
Derivative, Notional Amount	152
Sell | Derivatives Not Designated as Hedging Instruments | Canadian Dollar | Forward Contracts USD
Derivative
Derivative, Notional Amount	24
Sell | Derivatives Not Designated as Hedging Instruments | Japanese Yen | Forward Contracts USD
Derivative
Derivative, Notional Amount	46
Sell | Derivatives Not Designated as Hedging Instruments | Korean Won | Forward Contracts USD
Derivative
Derivative, Notional Amount	7
Sell | Derivatives Not Designated as Hedging Instruments | Chinese Yuan Renminbi | Forward Contracts USD
Derivative
Derivative, Notional Amount	126
Sell | Derivatives Not Designated as Hedging Instruments | Taiwan, New Dollars | Forward Contracts USD
Derivative
Derivative, Notional Amount	10
Sell | Derivatives Not Designated as Hedging Instruments | India, Rupees | Forward Contracts USD
Derivative
Derivative, Notional Amount	11
Buy | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Singapore Dollar | Forward Contracts USD
Derivative
Derivative, Notional Amount	22
Buy | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Other | Forward Contracts USD
Derivative
Derivative, Notional Amount	4
Buy | Derivatives Not Designated as Hedging Instruments | Euro | Forward Contracts USD
Derivative
Derivative, Notional Amount	25
Buy | Derivatives Not Designated as Hedging Instruments | British Pound | Forward Contracts USD
Derivative
Derivative, Notional Amount	6
Buy | Derivatives Not Designated as Hedging Instruments | Danish Krone | Forward Contracts USD
Derivative
Derivative, Notional Amount	22
Buy | Derivatives Not Designated as Hedging Instruments | Singapore Dollar | Forward Contracts USD
Derivative
Derivative, Notional Amount	14
Buy | Derivatives Not Designated as Hedging Instruments | Other | Forward Contracts USD
Derivative
Derivative, Notional Amount	$ 5

DERIVATIVES, Fair value of deri

DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($) $ in Millions	Jan. 31, 2023	Oct. 31, 2022
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	$ 8	$ 31
Derivatives liabilities fair value	28	5
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	3	23
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Derivatives liabilities fair value	19	2
Derivatives Designated as Hedging Instruments | Net Investment Hedging [Member] | Foreign Exchange Contracts | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	0	0
Derivatives Designated as Hedging Instruments | Net Investment Hedging [Member] | Foreign Exchange Contracts | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Derivatives liabilities fair value	1	0
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	5	8
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Derivatives liabilities fair value	$ 8	$ 3

DERIVATIVES, Effect of derivati

DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Derivative
Gain (loss) reclassified from accumulated other comprehensive loss into cost of sales	$ 6	$ 3
Gain (Loss) Reclassified from AOCI into cost of sales [Extensible Enumeration]	Cost of revenue	Cost of revenue
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts
Derivative
Gain (loss) reclassified from accumulated other comprehensive loss into cost of sales	$ 6	$ 3
Gain (Loss) Reclassified from AOCI into cost of sales [Extensible Enumeration]	Cost of revenue	Cost of revenue
Gain (loss) recognized	$ 2	$ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of revenue	Cost of revenue
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts | Accumulated Other Comprehensive Income (Loss)
Derivative
Gain (loss) recognized in accumulated other comprehensive loss	$ (31)	$ 8
Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Foreign Exchange Contracts | Accumulated Other Comprehensive Income (Loss)
Derivative
Gain (loss) recognized in accumulated other comprehensive loss - translation adjustment	(1)	3
Derivatives Not Designated as Hedging Instruments
Derivative
Gain (loss) recognized	$ (13)	$ (3)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other income (expense), net	Other income (expense), net

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities (Details) - Cash Flow Hedging $ in Millions	3 Months Ended
	Jan. 31, 2023 USD ($)
Derivative
Net gain to be reclassified within next Twelve Months	$ 14
Cost of Products and Services
Derivative
Net gain to be reclassified within next Twelve Months	$ 19

RETIREMENT PLANS AND POST RET_3

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Pension Plan | United States
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	$ 0	$ 0
Interest cost on benefit obligation	5	3
Expected return on plan assets	(5)	(6)
Amortization:
Actuarial losses	0	0
Total net plan costs (benefits)	0	(3)
Pension Plan | Foreign Plan
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	6	8
Interest cost on benefit obligation	6	2
Expected return on plan assets	(9)	(11)
Amortization:
Actuarial losses	(1)	6
Total net plan costs (benefits)	2	5
Other Postretirement Benefits Plan | United States
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	0	0
Interest cost on benefit obligation	1	1
Expected return on plan assets	(1)	(1)
Amortization:
Actuarial losses	0	(1)
Total net plan costs (benefits)	$ 0	$ (1)

RETIREMENT PLANS AND POST RET_4

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Employer Contributions)) - Pension Plan - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
United States
Defined Benefit Plan Disclosure
Employer Contributions	$ 0	$ 0
Expected future employer contributions	0
Foreign Plan
Defined Benefit Plan Disclosure
Employer Contributions	5	$ 5
Expected future employer contributions	$ 11

WARRANTIES AND CONTINGENCIES (D

WARRANTIES AND CONTINGENCIES (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Oct. 31, 2022
Movement in Standard Product Warranty Accrual
Beginning balance	$ 30	$ 30
Accruals for warranties including change in estimate	11	13
Settlements made during the period	(13)	(13)
Ending balance at end of period	28	30
Standard Product Warranty Disclosure
Accruals for warranties due within one year	28	29
Accrual for warranties due after one year	0	$ 1
Guarantees
Guarantees	$ 37		$ 37

SHORT-TERM DEBT - Credit Facili

SHORT-TERM DEBT - Credit Facility (Details) - USD ($) $ in Millions		3 Months Ended
	Mar. 13, 2019	Jan. 31, 2023	Jan. 31, 2022	Jun. 18, 2021	Apr. 21, 2021
Short-term Debt
Repayments of commercial paper		$ (324)	$ (240)
Proceeds from Commercial Paper		527	$ 240
Line of Credit [Member] | 5 yr Unsecured Credit Facility
Short-term Debt
Initiation date of credit facility	Mar. 13, 2019
Maximum borrowing capacity of credit facility	$ 1,000				$ 1,350
Credit faciity terms (in years)	five
Expiration date of credit facility	Mar. 13, 2024
Amount outstanding on credit facility		0
Line of Credit [Member] | Additional Incremental Term Loan Facility
Short-term Debt
Maximum borrowing capacity of credit facility	$ 500				$ 500
Amount outstanding on credit facility		0
Line of Credit [Member] | Commercial Paper
Short-term Debt
Maximum borrowing capacity of credit facility				$ 1,350
Amount outstanding on credit facility		$ 238
Weighted Average Interest Rate, at Point in Time		4.67%

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details) - USD ($) $ in Millions	Jan. 31, 2023	Oct. 31, 2022
Debt Instrument
Long-term debt	$ 2,733	$ 2,733
Senior Notes 2026
Debt Instrument
Long-term debt	299	299
Senior Notes 2029
Debt Instrument
Long-term debt	495	495
Senior Notes 2030
Debt Instrument
Long-term debt	496	496
Senior Notes 2031
Debt Instrument
Long-term debt	843	843
Senior Notes
Debt Instrument
Long-term debt	$ 2,133	$ 2,133

LONG-TERM DEBT - Text (Details)

LONG-TERM DEBT - Text (Details) - USD ($) $ in Millions	Jan. 31, 2023	Oct. 31, 2022	Apr. 15, 2022
Debt Instrument
Long-term debt	$ 2,733	$ 2,733
Senior Notes 2031
Debt Instrument
Long-term debt	$ 843	843
Term Loan Maturing 2025
Debt Instrument
Maximum borrowing capacity of credit facility			$ 600
Long-Term Debt, Weighted Average Interest Rate, at Point in Time	5.40%
Long-term debt	$ 600
Senior Notes
Debt Instrument
Long-term debt	$ 2,133	$ 2,133

STOCKHOLDERS' EQUITY - Stock Re

STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Mar. 01, 2023	Jan. 09, 2023	Feb. 18, 2021
2021 Repurchase Program [Member]
Share repurchase program
Share repurchase program authorized amount					$ 2,000
Shares repurchased and retired during period, (Shares)	499,000	2,900,000
Shares repurchased and retired during period, (Value)	$ 75	$ 447
Remaining authorized repurchase amount under share repurchase program	$ 363
2021 Repurchase Program [Member] | Subsequent Event [Member]
Share repurchase program
Remaining authorized repurchase amount under share repurchase program			$ 339
2023 Repurchase Program
Share repurchase program
Share repurchase program authorized amount				$ 2,000

STOCKHOLDER"S EQUITY - Dividend

STOCKHOLDER"S EQUITY - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Feb. 22, 2023	Jan. 31, 2023	Jan. 31, 2022
Dividends Paid
Cash dividends paid per common share		$ 0.225	$ 0.210
Aggregate amount of cash dividends paid		$ 67	$ 63
Dividends Declared
Dividends Declared. per share		$ 0.225	$ 0.210
Subsequent Event [Member]
Dividends Declared
Date Dividends Declared	Feb. 22, 2023
Dividends Declared. per share	$ 0.225
Aggregate Cash Dividends Declared	$ 67
Payment Date of Declared Dividends	Apr. 26, 2023
Dividends Declared Date of Record	Apr. 04, 2023

STOCKHOLDER'S EQUITY - Accumula

STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Beginning Balance	$ (347)
Other comprehensive income (loss) before reclassifications	62
Amounts reclassified out of accumulated other comprehensive income (loss)	(7)
Tax expense (benefit)	(12)
Other comprehensive income (loss)	67	$ (16)
Ending Balance	(280)
Foreign Currency Translation
Beginning Balance	(335)
Other comprehensive income (loss) before reclassifications	90
Amounts reclassified out of accumulated other comprehensive income (loss)	0
Tax expense (benefit)	(1)
Other comprehensive income (loss)	91
Ending Balance	(244)
Prior Service Credits
Beginning Balance	123
Other comprehensive income (loss) before reclassifications	0
Amounts reclassified out of accumulated other comprehensive income (loss)	0
Tax expense (benefit)	0
Other comprehensive income (loss)	0
Ending Balance	123
Actuarial Losses
Beginning Balance	(155)
Other comprehensive income (loss) before reclassifications	3
Amounts reclassified out of accumulated other comprehensive income (loss)	(1)
Tax expense (benefit)	0
Other comprehensive income (loss)	2
Ending Balance	(153)
Unrealized Gains (Losses) on Derivatives
Beginning Balance	20
Other comprehensive income (loss) before reclassifications	(31)
Amounts reclassified out of accumulated other comprehensive income (loss)	(6)
Tax expense (benefit)	(11)
Other comprehensive income (loss)	(26)
Ending Balance	$ (6)

STOCKHOLDERS' EQUITY - Reclassi

STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives
Unrealized gain (loss) on derivatives	$ 6	$ 3
Amounts reclassified into earnings related to derivative instruments, tax	(2)	(1)
Unrealized gain (loss) on derivatives after reclassification and after Tax	4	2
Actuarial net loss	1	(6)
Actuarial net loss and prior service benefit reclassified, before tax	1	(6)
Tax on actuarial net loss and prior service benefit reclassified	(1)	1
Actuarial net loss and prior service benefit reclassified, net of tax	0	(5)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$ 4	$ (3)

SEGMENT INFORMATION - Profitabi

SEGMENT INFORMATION - Profitability (Details) $ in Millions	3 Months Ended
	Jan. 31, 2023 USD ($)	Jan. 31, 2022 USD ($)
Segment Reporting Information
Number of operating segments	3	3
Segment Reporting Information
Net revenue	$ 1,756	$ 1,674
Income from operations	426	376
Life Sciences and Applied Markets
Segment Reporting Information
Net revenue	1,033	976
Income from operations	314	282
Diagnostics and Genomics
Segment Reporting Information
Net revenue	342	339
Income from operations	59	68
Agilent CrossLab
Segment Reporting Information
Net revenue	381	359
Income from operations	103	91
Segment Total
Segment Reporting Information
Net revenue	1,756	1,674
Income from operations	$ 476	$ 441

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Reconciliation of Operating Profit from Segments to Consolidated
Income from operations	$ 426	$ 376
Transformational initiatives	(7)	(4)
Amortization of intangible assets related to business combinations	(36)	(51)
Acquisition and integration costs	(2)	(7)
Change in fair value of contingent consideration	(1)	(3)
Other	(4)	0
Interest income	9	1
Interest expense	(25)	(21)
Other income (expense), net	0	(37)
Income before taxes, as reported	410	319
Segment Total
Reconciliation of Operating Profit from Segments to Consolidated
Income from operations	$ 476	$ 441

SEGMENT INFORMATION - Segment A

SEGMENT INFORMATION - Segment Assets (Details) - USD ($) $ in Millions	Jan. 31, 2023	Oct. 31, 2022
Segment Reporting Information
Assets	$ 10,919	$ 10,532
Life Sciences and Applied Markets
Segment Reporting Information
Assets	4,004	3,955
Diagnostics and Genomics
Segment Reporting Information
Assets	3,520	3,489
Agilent CrossLab
Segment Reporting Information
Assets	962	869
Segment Total
Segment Reporting Information
Assets	$ 8,486	$ 8,313